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Numerous diseases that rarely occur in highly developed countries or that can 
generally be treated effectively there continue to lead to far more serious health 
problems in developing countries. The causes of this are manifold. In addition 
to insufficient healthcare provisions and other local conditions that require par-
ticular product specifications, the structures of the commercialised system of 
pharmacological innovations in the industrial countries and the international 
pharmaceutical market are also blamed for this. In developing countries, this 
results in two interconnected problems: First, numerous activities in research 
and development (R&D) take place to combat diseases that occur frequently 
both in industrial and in developing countries. However, as such activities can 
only be (re)financed for a certain period of time via product prices, high prices 
prevent poor countries in particular from procuring the required medicines in 
sufficient quantities and making them available to the population (access prob-
lem). Second, for diseases which almost exclusively occur in poor countries, 
hardly any new products are being developed in the first place, since the cost-
intensive research and development cannot be (re)financed through the product 
prices (R&D problem). 
On the basis of the Millennium Goals agreed in 2000, numerous actions to 
improve the situation were stipulated. Their primary objective is to improve 
access to available medicines and medical care, but they should also work to-
wards the medical innovation system focusing more clearly again on poverty-
related and neglected diseases. It is widely agreed that neither the public sector 
nor the private sector alone have the necessary capacities to develop medicines 
to combat diseases that mostly affect poor countries. Views differ concerning 
the general suitability of the prevalent patent-based innovation system and thus 
the various measures that have been discussed and also partially implemented in 
recent years. At times it is noted that the great number of measures results in 
some confusion and in increasingly complex coordination. 
The Committee for Education, Research and Technology Assessment of the 
German Bundestag has tasked the Office of Technology Assessment (Büro für 
Technikfolgen-Abschätzung beim Deutschen Bundestag [TAB]) with providing 
an overview of already established programmes and concepts for the strength-
ening of R&D in combatting poverty-related and neglected diseases (PRND). 
This final report looks at the medical innovation system with its product devel-
opment phases and funding mechanisms and outlines initiatives by public and 
private R&D actors as well as political measures to increase commitment in re-
spect of poverty-related and neglected diseases. From the comprehensive analy-
sis of the current situation, courses of action for political decision-makers will be 
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derived in order to counter the R&D problem associated with poverty-related 
and neglected diseases. 
What diseases, what requirements in terms of research 
and funding? 1. 
To date, no standard definition or list of poverty-related and neglected diseases 
exists. Consistently the term comprises diseases which mainly occur in poor 
countries and for which commercial companies have not developed any or 
hardly any new products in recent years due to financially weak demand. Most-
ly, the so-called »big three« (tuberculosis, malaria, HIV/AIDS), most of the 17 
neglected tropical diseases defined by the WHO as well as some respiratory and 
diarrhoeal diseases are referred to as poverty-related and neglected. All of them 
are infectious diseases caused by a range of pathogens (viruses, bacteria, proto-
zoons, worms). Some of them transmitted by insects and other intermediate 
hosts. Especially in developing countries, estimates regarding the spread and 
health consequences of these diseases often remain vague. The “Big Three” to-
gether with respiratory and diarrhoeal diseases remain widespread in develop-
ing and newly industrialized countries and cause most deaths in the poorest 
countries, often already among children. The 17 neglected tropical diseases are 
often less widespread, cause fewer deaths but are associated with impaired 
health, disability and social exclusion. Depicting their impact on society with 
established reporting systems and models remains difficult. Especially diseases 
that occur very rarely or only locally often do not appear on the radar of global 
health reporting. Prior to 2014, for example, Ebola fever was not included in any 
list of neglected diseases. 
Experts assess the R&D requirements for the above mentioned diseases in-
dividually for each disease and in terms of different product groups and/or pa-
tient populations (e.g. medical devices, medicines, pediatric formulations). The 
need for R&D results from existing knowledge, current options and limitations 
in combating the respective diseases as well as the respective conditions in the 
areas where the disease is prevalent. Needs specific to developing countries are 
in particular identified for insect repellent products, simple and yet specific tests 
that require no special laboratory equipment, vaccines that require no refrigera-
tion as well as durable, standardised fixed dose combinations of required active 
substances - and thus hardly any overlap exists with the objectives of the medi-
cal innovation system of industrialised countries (personalized high-tech medi-
cine). It is almost impossible at present to provide a realistic estimate of the costs 
of covering such a need for R&D specific to developing countries. 
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Case study: Malaria 2. 
Taking the poverty-related and neglected disease of malaria, the report – by way 
of example – outlines existing options and the challenges arising from them for 
research and product development. Malaria is caused by plasmodia- single-
celled parasites that are much bigger and more complex than viruses and bacte-
ria. Five species of plasmodium can cause malaria in humans. They differ in 
their regional spread. Plasmodia are transmitted through the bite of infected 
anopheles mosquitos. When the mosquitos bite to obtain blood, the parasites 
enter into the human blood circulation, spread, destroy the red blood cells and 
are transmitted onwards when the infected person is bitten again. A number of 
different approaches exist in combatting malaria: attacking the mosquitos, hu-
man immunisation and killing the plasmodia in the human blood. 
Insecticide-treated bed nets and indoor room sprays are used against the 
nocturnal insects. Bed nets are currently considered the most effective preven-
tive measure. In recent years, large parts of the population in endemic regions 
were supplied with these nets, with billions in financial support also provided by 
the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). The insec-
ticides have been widely used in agriculture for a long time. Their use in malaria 
prevention is an application extension. For many years now, agricultural and 
health organisations as well as the United Nations Environment Programme 
(UNEP) have warned about the development of resistances as the result of the 
parallel use of the same substances in both medicine and agriculture. Already 
the first Global Malaria Eradication Programme failed in the 1960s, among oth-
er things because the insecticide used at that time lost its efficacy. The develop-
ment of new insecticides for combatting disease-transmitting insects is an ur-
gent R&D task. 
Even if almost all people in malaria-endemic regions are infected with 
plasmodia through mosquito bites, Malaria is affecting mostly in those people 
whose immune systems are insufficiently able to combat these pathogens. First 
and foremost, these include babies/infants and pregnant women, but also people 
who are only short time in malaria-endemic regions. Early detected infections 
can mostly successfully treated with available medicines. However, delays can 
result in complicated and even lethal progressions. In small children in particu-
lar a simple infection can quickly develop into a complicated malaria. At pre-
sent, the most effective agent for the treatment of malaria is artemisinin, but in 
some Asian regions plasmodium species are already becoming resistant against 
it. The WHO generally recommends combining artemisinin with other agents, 
in order not to encourage the development of resistances. In highly endemic 
areas, particular high-risk groups of people are often given prophylactic medica-
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tion. On the one hand, this may prevent a certain number of infections, but on 
the other, this dual use also accelerates the development of resistances. For that 
reason, another urgent R&D task is thus the development of new active phar-
maceutical ingredients. Diagnostic tests that are fast, simple and yet as accurate 
as possible are of the utmost relevance. Currently available rapid tests are not 
very reliable especially during the early stage of the infection and have as yet 
been unable to detect resistances to particular medicines. Here, too, an urgent 
need for R&D exists. 
To date, there are no vaccines against diseases caused by single-cell organ-
isms such as plasmodia. An effective vaccine against malaria would be a great 
step forward. 
Since the fight against malaria as one of the “Big Three” has been agreed by 
the international community to be one of the millennium goals, numerous ac-
tivities, including multilateral ones, have been initiated in order to support the 
countries affected by malaria in their battle against the disease: 
› establishment of the Roll Back Malaria partnership for the global coordina-
tion of control measures as well as R&D activities; 
› establishment and funding of GFATM that supports malaria-endemic 
countries in the procurement and provision of available products in suffi-
cient quantities (mainly mosquito nets, rapid tests and medicines), as well as 
› strengthening of basic research and the establishment of various non-profit 
product development partnerships (PDPs) financed by donations that, in 
cooperation with private enterprise, search for new active substances and 
further improve already available medicines (e.g. new combinations of ac-
tive substances, paediatric formulations). 
Despite intensive efforts, the major R&D challenges in the fight against malaria 
– such as the development of new agents (insecticides, medicines, vaccines) as 
well as simpler and more accurate diagnostic tools – still remain unsolved. If the 
medical innovation system of the industrial countries were supposed to con-
tribute to solving these problems, this would involve considerable expenditure, 
since this system requires strict documentation of evidence of the safety, efficacy 
and quality of the respective products. This necessitates substantial R&D activi-
ties. In the healthcare system of the industrial countries, only tested, licensed 
and certified products can be used in the treatment of diseases. Even bi- and 
multilateral programmes with the involvement of industrial countries that aim 
to fight poverty-related and neglected diseases such as malaria increasingly call 
for such product certifications. 
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The medical innovation system – course of action and 
opening up of procedures 3. 
 
Course of action 3.1 
A structured procedure with several sequential and incremental stages of R&D 
has emerged in order to provide evidence of the safety (potential risks to hu-
mans and the environment) and efficacy or reliability (in relation to disease-
specific conditions). Any development of a medicine is scientifically based on 
detailed knowledge of the causes of the disease and of disease-related processes 
within the human body (basic research). The subsequent product development 
requires an increasingly structured and formalised approach that also needs to 
include economic considerations. During the early stages of the development 
process, numerous substances are tested, applicable and producible candidates 
selected and developed further as well as first safety questions answered (during 
the so-called preclinical stage with the aid of cell cultures and animal testing). 
Following the successful conclusion of the preclinical stage, human trials can be 
applied for (clinical research), initially on healthy volunteers (Phase I) in order 
to answer additional safety questions and for dose-finding, subsequently on the 
actual target population in order to prove preventive or therapeutic efficacy and 
safety (Phase II and III). If these phases have been concluded successfully, mar-
ket authorisation can be requested. However, safety and efficacy under real-life 
conditions continues to be monitored (Phase IV). 
By far not all initially promising product candidates can be developed into 
safe and effective medicines or medical devices. The success criteria (safety, effi-
cacy, cost-effectiveness) are continuously tested and only the most promising 
candidates selected for further development. This also implies that the develop-
ment of numerous product candidates is terminated over the course of the in-
novation process. Any product development is thus associated with a consider-
able risk of failure. 
R&D activities up to and including Phase I clinical studies can be conducted 
wherever laboratories and hospitals with the necessary professional staff are 
available and where healthy volunteers can be found who agree to act as pro-
bands. In industrial countries, clinical studies follow a set pattern of formal ap-
proval and procedural steps. A legal entity (normally the manufacturer) bears 
the costs and overall responsibility for conducting the clinical study and is liable 
for all consequences. Both a regulatory authority and an independent ethics 
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committee have to give their approval. All trials with humans have to be entered 
in registers. 
According to given standards, at least the clinical trials with patients (from 
Phase II) must be carried out in regions where the respective diseases occur – in 
case of poverty-related and neglected diseases countries of the Global South. In 
these countries, clinical centres for the conduct of clinical trials as well as gov-
ernance structures (regulatory authorities, ethics committees, study registers) 
have to be established or expanded – a great challenge, also because trained pro-
fessionals often emigrate to the countries of the Global North. For the conduct 
of clinical trials networks and alliances are currently being developed especially 
in Sub-Saharan Africa (e.g. Malaria Clinical Trials Alliance, African Vaccine 
Regulatory Forum, Pan African Clinical Trials Registry) with the aim of estab-
lishing and operating sustainably similar structures as in the countries of the 
Global North. 
R&D activities in relation to poverty-related and neglected diseases often 
require increased resources and time. In many cases, there is still a need for fun-
damental development work to be put into place so that approval processes take 
longer and trials are not conducted with as much routine as in the countries of 
the Global North. These challenges have by now resulted in a stronger coopera-
tive approach. The regulatory authorities in the US (Food and Drug Admin-
istration [FDA]) and the EU (European Medicines Agency [EMA]) have in-
creased their cooperation with the WHO, with public and private R&D actors as 
well as with international funds and alliances in order to coordinate the neces-
sary steps for carrying out clinical trials in accordance with the standards of in-
dustrial countries. Research institutions and regulatory authorities of the indus-
trial countries can give considerable support to local institutions in the evalua-
tion of trial data and the assessment of results. FDA and EMA have established 
special procedures for the fast and cost-efficient assessment of medicines, to 
some extent also for the market approval in regard to poverty-related and ne-
glected diseases. At present, these procedures have only been activated in a very 
small number of cases. If more assessments of medicines and medical device are 
to be performed in the medium term, the necessary resources will have to be 
increased. The long-term objective is to aim for national/regional autonomy of 
the countries of the Global South in matters of approval and assessment – a clas-
sic task of development, not of research cooperation. 
R&D expenditure using the example of one vaccine candidate 
Mosquirix®, the most promising malaria vaccine candidate to date, resulted 
from a 30-year cooperation between public and private R&D actors together 
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with the long-term participation of a PDP. The latter provided particular 
support to the conduct of the necessary clinical trials in Sub-Saharan Africa. 
In 2008 the conception of the clinical trial for the proof of efficacy began. 
From 2009 onwards 15.500 babies and infants in eleven clinical centres in 
Sub-Saharan Africa received four vaccinations each and were subsequently 
monitored until 2014. Most African centres received scientific support from 
European or US R&D institutions. It became apparent that even with a con-
siderable vaccination effort, malaria can only be partially prevented (approx-
imately one-third fewer cases). On the basis of the approval application 
numbering 250,000 pages, the EMA issued a positive risk-benefit assessment 
in 2015, but it is unclear whether the schedule of four vaccinations within 18 
months can be implemented under real-life conditions. The WHO has de-
manded additional pilot projects with approx. 1 million participants. A rec-
ommendation could only be given following the evaluation of these pilot 
projects. According to the manufacturer’s own information, the company 
has invested more than 600 million US-Dollar to date, the PDP an additional 
200 million US-Dollar (mainly donations by the Gates Foundation). No fig-
ure has been given for the costs of scientific support provided by European 
and US institutions. It is not clear at present how the stipulated pilot projects 
are to be financed. For the pilot project the manufacturer estimates costs of 
20 million US-Dollar only for the necessary vaccine production (5 US-Dollar 
per vaccination dose). 
Opening up of research infrastructures and cooperative use 
(Open Innovation) 3.2 
Medical basic research as well as substance discovery and development these 
days involve the use of expensive high-tech equipment (including maximum-
resolution microscopes, DNA sequencing technology, high-throughput screen-
ing technology, comprehensive substance repositories, including powerful data 
processing and storage technology). These research infrastructures are currently 
being established and expanded with considerable resource input, predominant-
ly in industrial countries as well as in some newly industrialized countries. In 
Europe, they are increasingly interconnected and used jointly. Opening up and 
using these facilities also for research into neglected diseases are key elements in 
improving the current situation, because at present establishing comparable 
infrastructures in developing countries seems almost impossible. The interna-
tional research networks and open data exchange platforms currently being es-
tablished as part of the malaria genome research – such as the Plasmodium Di-
versity Network Africa (researching genetic diversity and biomarkers for the 
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emerging parasite resistance to artemisinin in Sub-Saharan Africa) or the Ge-
nomic Epidemiology Network (mapping the genome variance of the most wide-
ly spread plasmodium species) – could lead the way for research activities also in 
other diseases. They all make their research data and results freely available 
online. 
Many companies, too, are starting to open up their R&D infrastructure to 
the development of medicines for poverty-related and neglected diseases. This 
opening can take different forms, therewith giving rise to a wide range of inter-
pretations of what is to be understood and subsumed under the term Open In-
novation. The currently probably most extensive experiment was initiated in 
2010 by the UK pharmaceutical company GlaxoSmithKline with the aim of test-
ing the extent to which the business model of open-source software develop-
ment, i.e. the cooperation of volunteers creating products that do not belong to 
one company alone, could be transferred to the development of medicines. Its 
central elements are a patent pool and an open lab. The patent pool includes the 
intellectual property rights to malaria-specific lead compounds discovered in-
house by the company with the associated data and information. They are freely 
accessible and usable for the development of medicine in the fight against pov-
erty-related and neglected diseases (except HIV/Aids), on the condition that 
developing countries are subsequently guaranteed an equitable access to the 
products. This patent pool has attracted a great response in only a few years. 
More than 40 public and private R&D actors are involved (but no Germans as 
yet). In the meantime, it has been handed over to the World Intellectual Proper-
ty Organisation (WIPO) which runs it in conjunction with an US non-profit 
organisation. In the open lab, external scientist can use the company’s R&D in-
frastructures for activities relating to poverty-related and neglected diseases on 
the condition that they agree to a subsequent equitable access to the products. 
This initiative is now also supported by the European Commission, which co-
finances research activities over several years by experienced scientists in the 
open lab. 
It is impossible at present to come up with a realistic estimate of the extent 
to which different forms of Open Innovation can sustainably and significantly 
boost R&D activities in relation to poverty-related and neglected diseases. Even 
if open infrastructures can reduce the current obstacles regarding R&D in 
PRND and open up good opportunities for participation and utilisation, they 
are not automatically free of charge. The mandatory (pre)clinical trials up to 
product authorisation become more extensive, expensive and carry greater re-
sponsibility with every phase. Only if the necessary funding for the entire inno-
vation process can be provided, will a contribution towards the fighting of these 
diseases arise from this. 
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Market-based funding mechanisms and neglected 
diseases 4. 
In industrial countries, even large-scale medical product developments are to a 
significant extent funded by the market. The main burden of the R&D tasks as-
sociated with considerable risks is borne by the producers of new medicines, but 
in return they are granted intellectual property rights, guaranteeing them exclu-
sive commercial use of the outcomes for a limited period of time, thus enabling 
a return on R&D investments. Rights to commercial use can be traded through 
licenses. In industrial countries, this approach permitted the commercialisation 
of numerous R&D activities and thus the refinancing of associated costs through 
subsequent product prices. In this model, public budgets co-financing the re-
spective national healthcare system are not burdened with the costs of product 
development, but with those of reimbursement for the use of the resulting med-
icines for which the initially sole manufacturer can determine the price. Of par-
ticular relevance in the medical innovation system are temporary property 
rights for the commercial use of 
› inventions – these are mainly protected through patents (substances, pro-
duction processes, formulations and application indications can be protect-
ed by patent law) – as well as 
› data and results from clinical trials as well as approval documents – these are 
protected by procedures established in pharmaceutical law regarding data 
exclusivity and document protection. 
For as long as their exclusive commercial use is guaranteed, manufacturers en-
joy considerable leeway in setting a price that permits positive returns on in-
vestment (profits) through the (re)financing of R&D expenditure. After the end 
of this protection period, other manufacturers can bring out equivalent prod-
ucts (generics) at reduced expenditure, because important product information 
(formulations, areas of application) are openly accessible and full references can 
be made to the original with regard to safety and efficacy and also monitoring 
and conditions of use. As only biological equivalence to the original has to be 
proven, development and approval costs remain comparatively low. The subse-
quent competition between manufacturers overall results in considerable price 
reductions. The price level of the respective substances is then largely deter-
mined by production costs and profit margins of the generics manufacturers. 
This basic structure of a commercialised pharmacological innovation pro-
cess has given rise to different strategies and market dynamics: Large research-
based pharmaceutical companies, in particular, develop so-called product port-
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folios that contain several product candidates at all stages of R&D as well as ap-
proved medicines. R&D activities, risks and costs are pooled within the compa-
ny and pay-as-you-go financed from the income from approved products. Even 
if the funding structures are known in principle, individual R&D expenditures 
remain highly non-transparent to outsiders (this applies also, but not exclusive-
ly, to commercial institutions). Furthermore, the time-limited refinancing op-
tions provide manufacturers with an argument for justifying ever higher market 
entry prices for new medicines. Intellectual property rights established in the 
industrial countries permit patents to be linked to other protective rights, thus 
making it possible to continuously extend the time limitation of the manufac-
turer’s monopoly. The resulting higher profits represent a considerable incen-
tive for R&D and attract investments. By contrast, areas of medicine where such 
profits cannot be achieved are neglected in research – even in industrial coun-
tries. Examples for this are rare diseases or antibiotics. However, taking intellec-
tual property rights as the sole reason for R&D neglect falls short, because the 
same neglect also occurs in medical processes in which the described protective 
rights are entirely absent (e.g. for non-product-related innovations, care pro-
cesses). 
The governments of numerous industrial countries attempt to support 
health areas of R&D neglected in their own national territory through diverse 
measures, such as increased public funding for research, fee reductions in as-
sessment and approval procedures, tax credits or innovation funds. Some of 
these measures could also promote R&D activities on poverty-related and ne-
glected diseases. Some are already established (for example, in recent years 
many industrial countries have expanded their support of research on these dis-
eases). Others are the subject of controversial debate (e.g. tax credits or R&D 
funds). Their contribution is that at least some part of R&D costs does not have 
to be refinanced through product prices and/or that additional incentives for 
R&D are provided. 
Protection of intellectual property – the international 
situation 5. 
For decades, the advantages and disadvantages of the time-limited protection of 
intellectual property as an instrument of economic political control have been 
the topic of controversial debate. On the one hand, it may attract considerable 
R&D investments that are an essential requirement particularly in the pharma-
ceutical industry. On the other hand, within the context of poverty-related and 
neglected diseases, these same protection mechanisms are blamed for both the 
R&D problem (diseases that particularly affect developing countries are neglect-
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ed by R&D) and the access problem (available medicines are often prohibitively 
expensive for poor countries). Advocates and opponents of protective mecha-
nisms agree that there is an international conflict of interest between safeguard-
ing R&D investments and the access to medicines in developing and newly in-
dustrialized countries. In consequence, the special configuration of national law 
and its international harmonisation play a very important role in the balancing 
of interests and mediation in this conflict. 
Granting and safeguarding intellectual property rights are concerns of the 
national state, as the protection basically only applies in the country in which it 
has been granted. For patents, though, there have long been efforts towards an 
international harmonisation. In this context the activities of the WIPO (a UN 
sub-organisation) as well as those of the independent World Trade Organiza-
tion (WTO) are of particular relevance. 
The situation until the 1990s 5.1 
In the 1970s, some internationally negotiated treaties administered by the 
WIPO harmonised patent registration procedures. Member states committed 
amongst other things to treat national and foreign inventors equally and estab-
lished relevant authorities and accepted WIPO-international application proce-
dures of patent pre-registration. However, it remained up to individual coun-
tries to decide for which technology sectors under which conditions and for 
which periods of time they would grant exclusive rights. In this context, a wide 
interpretation of the concept of technology, the patentability of even minor in-
novations and long protective periods are described as high level protection 
(prevalent in industrial countries) and the restriction to individual sectors, a 
stipulation of a high degree of innovation and short protective periods as low 
level protection (tends to apply more to newly industrialized countries). Despite 
centralised patent registration procedures, differences in national regulations 
thus still made it possible for patents granted in one country to be rejected in 
another. 
Some newly industrialized countries made strategic use of this situation, 
particularly in the area of pharmaceuticals, in order to deal with the access prob-
lem; from the 1970s onwards, this was particularly prevalent in India: patents 
were only granted for short periods of time for technical procedures, but medi-
cines were excluded from patenting. In combination with simplified national 
approval procedures for medicines and market protection measures, this gave 
rise to a pharmaceutical industry specialised in the circumvention of procedural 
patents and the immediate generic production of new brand-name product 
without the need for costly pharmacological R&D of their own. Many develop-
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ing and newly industrialized countries attach higher value to the human right to 
health, one of whose requirements is an affordable access to medicines, than to 
the ever expanding protection of intellectual property rights and refinancing of 
R&D investments of foreign corporations, promoted through the establishment 
of so-called patent thickets. Particularly, because their products were not specif-
ically intended for the markets of developing and newly industrialized countries 
and the contributions to R&D refinancing thus pure windfall gains for the pa-
tent holders. 
As an agreement between industrial and newly industrialized countries 
within the WIPO was quite unlikely because of the comparatively strong posi-
tion of the developing and newly industrialized countries, the industrial coun-
tries were looking for a body outside of the WIPO in order to assert their inter-
ests in relation to innovation protection. They found it in the world trade nego-
tiations. 
The situation since the turn of the millennium 5.2 
Within the framework of the world trade negotiations, the industrial countries 
succeeded in the 1990s to link the Agreement on Trade-Related Aspects of Intel-
lectual Property Rights (TRIPS) to trade agreements. The central TRIPS regula-
tions are: 
› Patent protection is granted for inventions in all areas of technology (na-
tional refusal of patents e.g. for active pharmaceutical ingredients no longer 
an option). 
› The minimum patent term is 20 years from filing the application. 
› Disputes are settled within the WTO trade regime (WTO panels with wide-
ranging options of imposing sanctions even against states). 
› In case of national emergencies, the procedures can be limited through so-
called flexibilities. 
› Technical support is granted to developing and newly industrialized coun-
tries regarding the implementation of the treaty together with long transi-
tional periods. 
This agreement, acceptance of which is an automatic prerequisite to WTO 
membership, increasingly ruled out the patent circumvention strategies used by 
individual newly industrialized countries for the protection of their population’s 
health. On the one hand, it leads to a global strengthening of R&D investment 
protection. On the other, it is supposed to mediate between this protection of 
investments and the supply of medicines in case of national emergencies. The 
particular purpose of the flexibilities is to limit the significantly exacerbated 
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problem of accessibility. They had already been included in the TRIPS agree-
ment and were confirmed and specified in the Doha Declaration. The flexibili-
ties continue to provide a certain leeway in determining the level of protection; 
they permit compulsory licensing of ongoing patents in case of national health 
crises. 
Industrial countries, foremost the USA, are at times ascribed ambitions to 
further increase existing protection standards. Critics take the view that these 
ambitions are likely to fail in international negotiations due to the resistance of 
newly industrialized and developing countries and that the industrial countries 
are therefore trying to raise these standards within the framework of bilateral 
trade agreements. As EU member states have transferred numerous tasks of the 
common trade policy to the European Commission, this report has examined 
potentially relevant EU trade agreements in this respect. The analysis provided 
no evidence of EU trade treaties systematically curtailing the degree of freedom 
given to national governments under the TRIPS agreement. As a rule, these 
treaties are worded so broadly and at time so ambivalently as to offer a wide 
scope for implementation that can be used equally in the interest of the patent 
holders and for the purposes of health and development policy concerns. 
TRIPS and other trade agreements can regulate trade-related aspects of in-
tellectual property rights. However, such regulation presupposes that the respec-
tive products have already been developed and are thus tradeable. This means 
that in national health crises these treaties and the agreed flexibilities are used to 
cope with the problem of access to available products in developing and newly 
industrialized countries. There are different assessments as to how well this 
works out. 
Insufficient research incentives particularly on diseases that occur almost 
exclusively in developing and newly industrialized countries (R&D problem) 
cannot be compensated by trade agreements alone. This is because trade agree-
ments regulate market mechanisms which per definition fail with regard to pov-
erty-related and neglected diseases. In cases of financially weak demand (i.e. 
when product prices cannot sufficiently refinance R&D costs and no profits can 
be expected), the funding model based on intellectual property rights does at 
least not function sufficiently. The less favourable the ratio of required R&D 
expenditure and (re)financing options by way of product sales, the greater the 
importance of such supplementary or alternative funding mechanisms that un-
couple R&D costs or rather their refinancing from product prices. 
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Government measures to boost research and 
development 6. 
In recent years, some countries have increased their national commitment to 
boosting R&D on poverty-related and neglected diseases (PRND R&D). A com-
parison of governmental commitment in Germany on the one hand and the UK 
and the US on the other – two countries of equal importance as sites of medical 
R&D – clearly shows that both the UK and the US governments have attached 
far greater importance to the support of PRND R&D and that in both countries 
there seems to be a mutual effect of reinforcement between public commitment 
on the one hand and philanthropic as well as commercial commitment on the 
other. All three countries use the following long-established governmental in-
struments: 
› promotion of national research to strengthen basic research and early prod-
uct development especially in their own country; 
› participation in the European and Developing Countries Clinical Trials 
Partnership (EDCTP), a cooperation program almost exclusively imple-
mented through public R&D institutions with the aim of expanding capaci-
ties for conducting clinical studies in African countries in compliance with 
international standards (the US is not officially involved in the programme, 
but US R&D institutions participate in individual projects); 
› promotion of internationally acting non-profit product development part-
nerships explicitly for the support of product development in cooperation 
with public R&D establishments and industry; 
› promotion of R&D structures in developing countries. 
However, on a case-by-case basis, both the US and the UK employ these in-
struments for R&D promotion on a much greater scale than Germany. In Ger-
many, the 2011 concept by the Federal Ministry of Education and Research 
(BMBF) for the promotion of poverty-related and neglected diseases initially 
mainly reorganised and reframed instruments that had already been established 
for many years; it was only the continuation of the concept in 2015 that envis-
aged a financial expansion for some of these instruments. Since then, the corre-
sponding national research promotion is to be directed to a much greater degree 
by the German Centre for Infection Research (Deutsches Zentrum für Infek-
tionsforschung [DZIF]), a new network of long established R&D facilities. To 
which extent there is a more explicit focus on the specific problems of develop-
ing countries than in earlier structures remains an open question. As in many 
other industrial countries, PDP promotion had originally been assigned to the 
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department of economic cooperation and development. In 2011, instead of the 
required increase in funding, PDP promotion was switched to another depart-
ment. This was justified by pointing to the need to first gain experiences and 
evaluate instruments. From 2016 onwards, even a doubling in funding (10 mil-
lion Euro per annum for PDP promotion in total) does not yet even equate to 
one-sixth of the UK PDP support. 
As part of US and UK research support, Open Innovation elements, primar-
ily open access to research results, are furthermore pursued with much greater 
political commitment than in Germany. These make it easier for other R&D 
actors to utilize and further expand existing bodies of knowledge. In addition, 
both the UK and the US governments are testing further measures in order to 
incentivise and reward commercial R&D commitment in particular. To that 
end, the UK government relies on tax credits and comprehensive guaranteed 
purchases of newly developed products, the US government on vouchers by 
state authorities for the prioritised and lower-cost processing of applications 
and on the support of specific funds (different concepts for funds and their cur-
rent implementation status are presented in the report). 
No internationally agreed approach towards a boosting of R&D activities is cur-
rently apparent, neither in the generation of new funding sources nor in the 
handling and administration of existing support structures. There are as yet no 
international research funds with the explicit objective of providing a significant 
amount of funding for medical R&D on poverty-related and neglected diseases 
– despite the continuously repeated demands since the turn of the millennium, 
mainly channelled through the WHO. Even within the EDCTP, the only 
achievement so far has been the coordination of participants’ R&D activities, 
but not a joint administration of financial contributions from European mem-
ber states together with contributions by the European Commission. 
The stated measures to tackle the R&D problem mostly start from the pa-
tent-based medical innovation system without fundamentally calling it into 
question or wanting to overcome it. Continuing attempts to address the associ-
ated access problem to new medicines and medical devices rely on further mul-
tilateral initiatives for a socially sustainable access to products. 
Initiatives on equitable access to products 7. 
Since the turn of the millennium, various bi- and multilateral initiatives have 
been started with the purpose of making medicines and medical devices availa-




› The global vaccine alliance Gavi pools the vaccine demand of currently 54 
developing countries, purchases vaccines in bulk and provides manufactur-
ers with guaranteed sales over several years. Thanks to financial support 
from industrial countries and philanthropic foundations, the vaccines can 
additionally be subsidised (the 20 poorest countries are given them free of 
charge; in line with their increasing economic power, participating coun-
tries have to bear an increasing share of the costs themselves). 
› The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) pro-
vides relevant medicines and medical devices for developing and newly in-
dustrialized countries (programmes in more than 100 countries). Here, too, 
the required products are subsidised for the poorest countries through fi-
nancial support from industrial countries and philanthropic foundations 
and participating developing and newly industrialized countries have to 
bear an increasing share of the costs themselves in line with their increasing 
economic power. 
› The Global Financing Facility Trust Fund (GFF Trust Fund) was started in 
2015 to accelerate advancements in the health of women and children; it al-
so aims to improve access to medicines and medical care and to close specif-
ic R&D gaps (treatments suitable for children). The initiative is currently 
being tested in four African pilot countries. 
The aim of these initiatives is to improve the supply of medicines and medical 
devices to the health systems particularly of the poorest countries. At the same 
time, the programmes divide the global market for these products into a non-
commercial and a commercial sector. In the non-commercial sector, the aim is 
to keep product prices as low as possible. The poorest countries, in particular, 
are exempted from the (re)financing of R&D costs (via product prices) and in 
some instances, they receive additional subsidies so that they also do not have to 
bear the full production costs. With increasing economic power, countries are 
expected to bear a great share of the costs also in this non-commercial sector. 
However, positive returns on R&D investments are only to be envisaged for the 
commercial sector (total demand from industrial countries and private demand 
from developing and newly industrialized countries). 
Such differentiations which mainly unburden countries with weak econom-
ic power from contributing to the (re)financing of the required R&D costs are 
roughly described as a socially sustainable product access, however with a wide 
range of interpretations as to this socially sustainability. This report also intro-
duces an initiative that aims to anchor a socially sustainable product access al-
ready at the start of the innovation process in the out-licensing of patents (so-
cially sustainable licenses). 
The primary aim of these initiatives is to counter the access problem in rela-
tion to poverty-related and neglected diseases. It remains to be seen to what ex-
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tent the boosting of demand will counteract the failing market mechanisms in 
relation to poverty-related and neglected diseases and thus provide indirect in-
centives for dealing with the R&D problem. 
Location Germany: Actors, research areas, strengths 8. 
Germany possesses highly competent public and private institutions that in 
their totality cover almost the entire spectrum of R&D on poverty-related and 
neglected diseases, even if most activities are related to the “Big Three”. These 
R&D institutions are active in all product areas (medicines and medical prod-
ucts) and all stages of R&D (basic research, preclinical research, clinical trials), 
with some focal points and particular strengths apparent: 
› The commitment to fighting tuberculosis is outstanding due to its variety 
and its results. Activities aiming for the further development of different di-
agnostic techniques also stand out. 
› German actors also demonstrate a special expertise and creative new ap-
proaches in the early R&D stages of vaccine development. By comparison, 
the wealth of creative ideas in the development of new medicines lags be-
hind. 
› German companies have further particular strengths in the battle against 
disease-spreading insects, even though this is currently rather seen as a 
niche area. As the habitats of these insect also spread into the northern 
hemisphere in the wake of climate change, in the future this area is likely to 
become more important in industrial countries, too. 
For activities in the fight against poverty-related and neglected diseases, German 
R&D establishments not only make use of national support instruments. Yet it 
is very difficult (and at times impossible) to identify PRND-related activities in 
the respective national funding data bases, because no separate PRND project 
lists or specific search criteria have been recorded and the selection has to be 
made on the basis of case-by-case review of project descriptions. Thus it is not 
clear to what extent the potentials of various national innovation incentives such 
as KMU-innovativ or BioÖkonomie 2030 have been fully exploited in terms of 
poverty-related and neglected diseases. In addition to national funding options, 
German R&D establishments also use the opportunities provided by European 
framework programmes for research and innovation including the special struc-
tures of EDCTP and Innovative Medicines Initiative (IMI). Some actors are also 
involved in transatlantic projects and international contests of ideas, in which 
they achieved some outstanding results. 
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This snap-shot of German R&D activities did not find any evidence that the 
patent-based innovation system is being overcome. Procedures for the protec-
tion of intellectual property are used intensively, but German R&D actors are 
not yet involved in the joint use of patents in patent pools. In the implementa-
tion of other Open Innovation options, too, German R&D actors to date are 
anything but trailblazers. There is thus no indication of a solution to the funda-
mental problem of access to new medicines and medical devices in developing 
and newly industrialized countries associated with protection mechanisms. For 
that reason, the initiatives aiming for a socially responsible access to medical 
products continue to be of great relevance.  
Areas of activity 9. 
At present, the German Federal Government sees the main responsibility for 
boosting PRND R&D within the remit of the Federal Ministry of Education and 
Research (Bundesministerium für Bildung und Forschung [BMBF]) that at pre-
sent coordinates its health-related activities mainly with the Federal Ministry of 
Health (Bundesministerium für Gesundheit [BMG]) and the Federal Ministry 
for Economic Cooperation and Development (Bundesministerium für 
wirtschaftliche Zusammenarbeit und Entwicklung [BMZ]). TAB takes the view 
that the impact of the already established components of the funding concept 
for poverty-related and neglected diseases could be increased with the addition 
of further research-policy components and with interlinking these with activi-
ties regarding economic, development and health policy and merge them to an 
overall strategy of the German Federal Government. 
Research policy 9.1 
With the department-specific PRND funding concept initiated by the BMBF 
and the department’s own Africa strategy, important elements of the direct sup-
port for PRND R&D are being pooled. The four components of the funding 
concept (national research, EDCTP, PDP and research networks in developing 
countries) not only finance basic research on PRND in Germany, but also 
strengthen the networking of R&D actors in both north-south and south-south 
collaborations. These collaborations are important elements in the transfer of 
knowledge and the establishment of capacities for all R&D activities along the 
entire medical innovation chain and also in the coordination of R&D activities 
in order to identify blind spots and avoid duplication. After the establishment 
phase, regular reports on the progress of this programme are to be generated. As 
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a specific element of responsible research and innovation (RRI), they are to be 
included in the future into the comprehensive reports by the Federal Govern-
ment and the relevant expert commissions on Germany as a research and inno-
vation location. 
The four components of the funding concept cover all steps of the medical 
innovation process. But the amount of funding is still far too small particularly 
for conducting clinical trials in the course of product development, even after 
the increase. It seems almost impossible that the envisaged funding budgets will 
allow for rapid advances product development. The potentials of non-profit 
PDP with the aim of developing products against PRND cannot be fully exploit-
ed in this manner. A strengthening of early R&D measures to some extent 
comes to nothing if later approval-relevant clinical trials are delayed for budget-
ary reasons or if they have to be stretched over long periods of time. 
Other research-policy measures should accompany the BMBF programme. 
These include first and foremost the opening of or rather access to research in-
frastructures, data and results or also the joint use of patents in patent pools for 
R&D on PRND. With regard to modern high-tech research infrastructures 
(substance libraries and biobanks, laboratory automation, supercomputers), 
established in Europe with considerable public support and in any case increas-
ingly used on a joint basis, special procedures for PRND R&D should be estab-
lished (e.g. low-cost or free access and fields of use, specific contracts) in order 
to make this high technology usable for R&D on PRND in the best possible way. 
For publicly financed innovation initiatives – from KMU-innovativ and 
BioÖkonomie 2030 to the European Innovative Medicines Initiative (IMI) – it 
should also be assessed to what extent they could enable specific R&D on 
PRND. Another important step would be the opening up of PRND-related na-
tional and/or European calls for proposals also to research institutions in the 
Global South. 
Interlinking with remits in development cooperation 9.2 
A significant part of the necessary R&D activities, at latest starting at the proof-
of-concept stage, can only be carried out in countries where the respective dis-
eases are endemic. For this reason, the required clinical centres and also supervi-
sory authorities have to be established and expanded both on a national and on 
a transnational basis. As, besides their research tasks, these clinics also have re-
sponsibilities regarding medical care, measures of BMBF and BMZ should be 




Even if R&D costs for poverty-related and neglected diseases can be success-
fully uncoupled from product prices for at least the least developed countries, 
there are still production and distribution costs to consider that will exceed the 
financial capacities of the affected countries in view of their inadequate social 
security system. Bilateral measures within the framework of health related de-
velopment aid together with multilateral alliances and funds help to improve a 
socially sustainable access to quality-tested medicines and medicnal devices in 
developing and newly industrialized countries. The health-related effects of 
these initiatives (including Gavi, GFATM) could be enhanced if the currently 
highly diverse geopolitical coverage could be successfully standardised and ex-
panded as well as the respective activity ranges and budgets increased. As fi-
nancing the initiatives on socially sustainable product access falls under the re-
mit of the BMZ, a cross-departmental coordination between BMZ and BMBF is 
obviously required. 
Interlinking with measures of economic and 
innovation policies 9.3 
Some industrial countries attempt to boost weak market mechanisms in the 
medicines and medical device sector with the help of economic policy measures. 
These include tax credits for R&D measures, rewards for PRND R&D with 
vouchers or the massive boosting and securing of product demand. In Germa-
ny, too, a debate could be triggered as to whether economic policy measures 
with the aim of specifically strengthening commercial commitment to PRND 
R&D could be coupled with procedures that safeguard an equitable access to 
products. 
In parallel with the PRND funding concept by the BMBF, the then Federal 
Ministry of Economy and Technology (Bundesministerium für Wirtschaft und 
Technologie [BMWi]) set up a health-economy export initiative in 2011 in or-
der to support German companies in the development of new sales markets and 
to establish Germany as one of the leading exporters of health products and ser-
vices. As the BMWi takes the view that not all options have yet been exhausted 
particularly in the countries of Sub-Saharan Africa, a closer interlinking of 
measures with those relating to development and economic cooperation could 
be helpful, thus permitting the development of synergies between diverse activi-
ties (provided that this would not restrict any TRIPS flexibilities). 
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International health-policy and procedural areas of 
responsibility 9.4 
Procedures established by the regulatory authorities in the industrial countries 
and by the WHO regarding centralised benefit and risk assessment currently 
constitute important elements in making medicines or medical devices accessi-
ble to the respective entitled countries via multilateral initiatives. They bridge 
incomplete capacities, particularly in Sub-Saharan Africa. If new substances are 
to be advanced to approval in increased numbers, the resulting increased as-
sessment expenditure has to be covered. In parallel, there is a need to establish 
and expand structures of national and regional governance within the Global 
South in order to decrease the corresponding dependence on institutions in the 
industrial countries. The EDCTP European-African initiative already takes on 
important training tasks with regard to the medical-ethical assessment of clini-
cal trials. However, this is only one aspect in the evaluation of medicines and 
medical devices. Establishing the necessary governance structures cannot be 
achieved by research collaboration alone, but requires development cooperation 
and international commitment to health policies. Here, too, there is a need to 
coordinate and interlink activities. 
On a case-by-case basis, it could be tested by how much the time and per-
sonnel requirements for the proof of efficacy and safety of medicines against 
poverty-related and neglected diseases could be reduced if the methodology of 
study designs was adapted. In industrial countries, this is often possible for very 
rare diseases (e.g. a provisional early approval after the successful conclusion of 
Phase II, lowering the requirements on statistical tests). However, this is regular-
ly linked to an intensive monitoring of the application of the respective sub-
stance under real-life conditions – a particular challenge for developing coun-
tries whose monitoring capacities in this respect are limited. It would be neces-
sary to find and establish a form of safety monitoring that is practicable under 
the respective local conditions. 
Another aim should be to improve PRND documentation (epidemiological 
register as well as documentation of R&D activities and their funding). In some 
instances, a greater level of harmonisation is required in determining disease-
specific R&D requirements and coordinating the corresponding tasks and activ-
ities. This coordination increasingly takes place through global disease-related 
initiatives (e.g. Stop TB Partnership, Roll Back Malaria Partnership), European 
research collaboration projects (currently financed through Horizon 2020) as 
well as globally active PDPs with their specific product pipelines. It is at present 
impossible to assess conclusively whether further centralisation and global con-
trol could achieve greater successes in product development. 
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Instead of global solutions, recent years have seen a rise in numerous at-
tempts at small-scale solutions ranging from product supply programmes to 
patent pools. Even if views differ as to the extent that these individual compo-
nents can contribute towards a sustainable improvement of the situation, some 
trends become clear in this debate: It is generally agreed that the least developed 
countries must be most comprehensively supported with regard to access to 
medicines and medical devices. These countries are generally not expected to 
contribute towards the necessary R&D costs; for the supply to these countries, 
production licenses for individual medicines are granted free of charge. Addi-
tional subsidies may in some cases even permit products to be supplied entirely 
free of charge. The majority accept that industrial countries finance the existing 
medical innovation system to a large degree through product prices. From 
countries with economies somewhere in between these two extremes, the indus-
trial countries, at least, demand and call for a contribution towards the costs of 
R&D. In most cases, bilateral agreements are in place. There is still a wealth of 
opportunities here, not least because many processes are of only limited trans-
parency. A greater level of transparency and harmonisation of procedures in 
determining the price of new medicines and medical devices should be aimed 
for. The necessary debate about fair R&D funding and fair prices of medicines 
should be sought at an international level. While it is likely to provide only a 
limited solution to the problem of R&D on poverty-related and neglected dis-
eases, it may be helpful to reduce the problem of access to medicines for diseases 
that occur in industrial as well as in developing and newly industrialized coun-
tries. 
Combining department-specific measures to an overall strategy 
by the Federal Government and boosting its funding 9.5 
Poverty-related and neglected diseases are associated with problem areas and 
challenges that come under the remit of various government departments (re-
search, product development, economic development up to questions of inter-
national trade including protection mechanisms for R&D investments, devel-
opment cooperation, global health policy). A funding concept as a research poli-
cy instrument had been a necessary and important first step to face up to the 
current global problem caused by poverty-related and neglected diseases. How-
ever, combatting this problem successfully requires more than department-
specific commitments. The next step should be a coordinated approach by sev-
eral departments – an overall strategy by the Federal Government with specific 
and accountable measures for its implementation. These measures should be the 
subject of regular reports. 
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